Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    4.50 (0.90%)
Bid:
505.00
Ask:
505.50
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Directorate Changes

25 Mar 2021 10:00

RNS Number : 4013T
Tate & Lyle PLC
25 March 2021
 

25 March 2021

 

Tate & Lyle PLC

 

BOARD CHANGES

 

Tate & Lyle PLC (the "Company") announces that Vivid Sehgal, currently Chief Financial Officer Designate, will become Chief Financial Officer of Tate & Lyle on 1 April 2021. Vivid joined Tate & Lyle on 1 March 2021 and replaces Imran Nawaz who, as announced on 7 October 2020, is leaving the Company to take up the position of Chief Financial Officer of Tesco plc. Imran will step down from the Tate & Lyle Board on 31 March 2021.

 

The following changes to Tate & Lyle's Board and Board Committees are also announced.

 

Board

 

Anne Minto will retire from the Board at the conclusion of the AGM on Thursday 29 July, having served as a non-executive director since December 2012 and as the Chair of the Remuneration Committee for over six years. A search is underway for a new non-executive director to replace Anne. 

 

Board Committees

 

Sybella Stanley will become Chair of the Remuneration Committee from the conclusion of the AGM on Thursday 29 July.

 

In anticipation of her appointment as Chair of the Remuneration Committee, Sybella Stanley will join the Audit Committee from 1 April 2021.

 

Dr Gerry Murphy, Chair of Tate & Lyle, said: "I wish to thank Imran Nawaz for the energy and focus he has brought to the handover to his successor, Vivid Sehgal. This has enabled Vivid to step into the role of Chief Financial Officer earlier than anticipated and from the start of Tate & Lyle's new financial year."

 

"I would like to thank Anne Minto for her nearly nine years of distinguished service and significant contribution to the Board and, in particular, for her time served as Chair of the Remuneration Committee."

 

There are no further disclosures to be made pursuant to paragraph 9.6.11 of the Financial Conduct Authority's Listing Rules.

 

For more information contactNick Hasell, FTI Consulting (Media)Tel: Mobile: +44 (0) 7825 523 383

Christopher Marsh, VP, Investor Relationschris.marsh@tateandlyle.com / +44 (0) 7796 192 688

 

 

About Tate & Lyle: Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

 

Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

 

We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2020, Tate & Lyle sales totalled £2.9 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or Linkedin.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFLDVRISFIL
Date   Source Headline
2nd Dec 202412:30 pmRNSTotal Voting Rights
29th Nov 20245:41 pmRNSTransaction in Own Shares
28th Nov 20245:21 pmRNSTransaction in Own Shares
27th Nov 20245:31 pmRNSTransaction in Own Shares
26th Nov 20245:48 pmRNSTransaction in Own Shares
26th Nov 20242:30 pmRNSHolding(s) in Company
25th Nov 20245:09 pmRNSTransaction in Own Shares
22nd Nov 20245:28 pmRNSTransaction in Own Shares
21st Nov 20245:24 pmRNSTransaction in Own Shares
20th Nov 20245:44 pmRNSTransaction in Own Shares
20th Nov 20244:30 pmRNSHolding(s) in Company
19th Nov 20245:33 pmRNSTransaction in Own Shares
19th Nov 20243:15 pmRNSHolding(s) in Company
19th Nov 20243:00 pmRNSHolding(s) in Company
18th Nov 20245:20 pmRNSTransaction in Own Shares
18th Nov 20244:00 pmRNSHolding(s) in Company
18th Nov 20248:30 amRNSDirector/PDMR Shareholding
18th Nov 20248:00 amRNSAdmission of New Tate & Lyle Shares
15th Nov 20245:30 pmRNSTransaction in Own Shares
15th Nov 20243:13 pmRNSCompletion of Combination Tate & Lyle and CP Kelco
14th Nov 20245:48 pmRNSTransaction in Own Shares
13th Nov 20245:16 pmRNSTransaction in Own Shares
12th Nov 20245:45 pmRNSTransaction in Own Shares
11th Nov 20245:37 pmRNSTransaction in Own Shares
8th Nov 20245:29 pmRNSTransaction in Own Shares
7th Nov 20245:31 pmRNSTransaction in Own Shares
7th Nov 20247:00 amRNSHalf-year Report
6th Nov 20245:44 pmRNSTransaction in Own Shares
5th Nov 20245:20 pmRNSTransaction in Own Shares
5th Nov 20241:00 pmRNSHolding(s) in Company
4th Nov 20245:28 pmRNSTransaction in Own Shares
1st Nov 20245:44 pmRNSTransaction in Own Shares
1st Nov 202412:15 pmRNSTotal Voting Rights
31st Oct 20245:28 pmRNSTransaction in Own Shares
30th Oct 20245:33 pmRNSTransaction in Own Shares
29th Oct 20245:27 pmRNSTransaction in Own Shares
28th Oct 20245:40 pmRNSTransaction in Own Shares
28th Oct 20244:30 pmRNSHolding(s) in Company
25th Oct 20245:25 pmRNSTransaction in Own Shares
24th Oct 20245:31 pmRNSTransaction in Own Shares
23rd Oct 20245:19 pmRNSTransaction in Own Shares
23rd Oct 202411:00 amRNSHolding(s) in Company
22nd Oct 20245:28 pmRNSTransaction in Own Shares
22nd Oct 202412:45 pmRNSTotal Voting Rights
21st Oct 20245:36 pmRNSTransaction in Own Shares
18th Oct 20245:46 pmRNSTransaction in Own Shares
17th Oct 20245:40 pmRNSTransaction in Own Shares
16th Oct 20245:20 pmRNSTransaction in Own Shares
15th Oct 20245:23 pmRNSTransaction in Own Shares
14th Oct 20245:29 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.